Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse

Yang Liu^{1

2}, Hai-Wen Lu^{1

2}, Jin-Fu Xu^{3

2}

Affiliations

¹ Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
² Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China.
³ Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China jfxu@tongji.edu.cn.

PMID: 36137589
DOI: 10.1183/13993003.01332-2022

Free article

Comment

Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse

Yang Liu et al. Eur Respir J. 2022.

Free article

. 2022 Nov 24;60(5):2201332.

doi: 10.1183/13993003.01332-2022. Print 2022 Nov.

Authors

Yang Liu^{1

2}, Hai-Wen Lu^{1

2}, Jin-Fu Xu^{3

2}

Affiliations

¹ Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
² Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China.
³ Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China jfxu@tongji.edu.cn.

PMID: 36137589
DOI: 10.1183/13993003.01332-2022

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Comment in

Reply to: Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse.
Godet C, Cadranel J, Frat JP, Ragot S, Couturaud F. Godet C, et al. Eur Respir J. 2022 Nov 24;60(5):2201678. doi: 10.1183/13993003.01678-2022. Print 2022 Nov. Eur Respir J. 2022. PMID: 36137593 No abstract available.

Comment on

Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial.
Godet C, Couturaud F, Marchand-Adam S, Pison C, Gagnadoux F, Blanchard E, Taillé C, Philippe B, Hirschi S, Andréjak C, Bourdin A, Chenivesse C, Dominique S, Bassinet L, Murris-Espin M, Rivière F, Garcia G, Caillaud D, Blanc FX, Goupil F, Bergeron A, Gondouin A, Frat JP, Flament T, Camara B, Priou P, Brun AL, Laurent F, Ragot S, Cadranel J; NebuLamB study group and GREPI network; Godet C, Couturaud F, Cadranel J, Frat JP, Brun AL, Laurent F, Marchand-Adam S, Pison C, Gagnadoux F, Blanchard E, Taillé C, Philippe B, Hirschi S, Andréjak C, Chenivesse C, Dominique S, Bassinet L, Murris-Espin M, Rivière F, Garcia G, Caillaud D, Blanc FX, Goupil F, Gondouin A, Flament T, Camara B, Priou P, Ragot S. Godet C, et al. Eur Respir J. 2022 Jun 16;59(6):2102218. doi: 10.1183/13993003.02218-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34764182 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse

Affiliations

Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources